Speaking of SWITZERLAND here's a very interesting real life case study ....
The World Health Organization suspended HCQ trials immediately after the fake study published in Lancet. Switzerland, which had been using the treatment, prohibited the use of the drug in COVID-19 shortly after that on May 27th. The retraction was so stealth that the ban was not lifted in Switzerland until June 11th.
This window allowed French researchers to analyze what happened in the entire population of COVID-19 patients during the ban. They used the case fatality rate (CFR) as the measure observed. The graph is stunning.
It also the only period where the Swiss CFR approached or exceeded that in France where there has been no use of hydroxychloroquine outside a few isolated trials.
The CFR returned to the highest level it had been since early in the pandemic at over 15%. Upon resumption of treatment with hydroxychloroquine, it returned to below 5%. A statistical analysis of the data:
A statistically significant difference
For those who are not convinced of the observational result, we conducted a statistical difference test by comparing the three periods: May 28th – June 8th, June 9th – 22nd, June 23rd – July 6th . The period from June 9th till the 22nd is that in which the index increased some 13 days after the suspension of hydroxychloroquine. There is of course an effect of delay between stopping the prescription of the drug and possible deaths, which explains the delay of 13 days.
We therefore observe that for the period from the 28th of May till the 8th of June, the index is 2.39% and then drops to 11.52% or 4.8 times more and then drops to 3%.
When testing for statistical significance between the various observations, the difference is significant at 99% with a p <0.0001. 13 days after the HCQ prescription was resumed, the index dropped to 3% and this was again a significant effect.